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Objectives. This study sought to determine whether survival 
and risk of sudden death have improved for patients with ad- 
vanced heart failure referred for consideration for heart trans- 
plantation as advances in medical therapy were systematically 
implemented over an 8-year period. 
Background. Recent survival trials in patients with mild to 
moderate heart failure and patients after a myocardial infarction 
have shown that angiotensin-converting enzyme inhibitors are 
beneficial, type I antiarrhythmic drugs can be detrimental, and 
amiodarone may be beneficial in some groups. The impact of 
advances in therapy may be enhanced or blunted when applied to 
severe heart failure. 
Methods. One-year mortality and sudden death were deter- 
mined in relation to time, baseline variables and therapeutics for 
737 consecutive patients referred for heart transplantation and 
discharged home on medical therapy from 1986 to 1988, 1989 to 
1990 and 1991 to 1993. Medical care was directed by a single team 
of physicians with policies established by consensus. From 1986 to 
1990, the hydralazine/isosorbide initrate combination or angio- 
tensin-converting enzyme inhibitors were the initial vasodilators, 
and class I antiarrhythmic drugs were allowed. After 1990, captopril 
was the initial vasodilator, given to 86% of patients compared with 
46% of patients before 1989. After mid-1989, class I agents were 
routinely withdrawn, and amiodarone was used for frequent ventric- 
ular ectopic beats or atrial fibrillation (53% of patients after 1990 vs. 
10% before 1989). 
Results. The total 1-year mortality rate decreased from 33% 
before 1989 to 16% after 1990 (p = 0.0001), and sudden death 
decreased from 20% to 8% (p = 0.0006). Adjusted for clinical and 
hemodynamic variables in multivariate proportional hazards 
models, total mortality and sudden death were lower after 1990. 
Conclusions. The large reduction in mortality, particularly in 
sudden death, from advanced heart failure since 1990 may reflect 
an enhanced impact of therapeutic advances shown in large 
randomized trials when they are incorporated into a comprehen- 
sive approach in this population. This improved survival supports 
the growing practice of maintaining potential heart transplant 
candidates on optimal medical therapy until clinical decompen- 
sation mandates transplantation. 
(J Am Coil Cardiol 1995;26:1417-23) 
In the past 10 years, multicenter randomized trials have 
established benefits and risks of therapies in several patient 
populations with left ventricular dysfunction. Angiotensin- 
converting enzyme inhibitors improved survival for asymptom- 
atic patients with left ventricular ejection fraction <40% after 
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myocardial infarction in the Survival and Ventricular Enlarge- 
ment (SAVE) trial (1). Similar therapy reduced progression of
heart failure and improved survival for patients in New York 
Heart Association functional class I, II or III in the Study on 
Left Ventricular Dysfunction (SOLVD) trial (2) and provided 
greater benefit han the hydralazine/isosorbide d nitrate com- 
bination for patients with functional class I to II heart failure 
in the Vasodilators in Heart Failure Trial (V-HeFT) II (3). 
The multicenter Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS) trial for patients in functional 
class IV showed in 1987 that angiotensin-converting enzyme 
inhibition improved survival, but the actuarial mortality rate 
was still 46% at 1 year (4). The Cardiac Arrhythmia Suppres- 
sion Trial (CAST) (5) demonstrated that several class I 
antiarrhythmic agents are deleterious when administered for 
ventricular ectopic activity after myocardial infarction. 
Patients with severe heart failure characterized by func- 
tional class III or IV symptoms were once considered beyond 
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medical therapy, with heart transplantation ffering the only 
hope. These patients are now commonly referred to special- 
ized centers where transplantation is an option, but the 
minority will actually receive a transplant because of donor 
shortage and common contraindications, such as advanced age 
and concomitant disease, The majority are discharged home 
after adjustment ofmedical therapy. Sudden death is a major 
risk in this population; even patients whose heart failure 
symptoms lessen on medical therapy after acceptance for 
transplantation may remain on the transplant waiting list 
because of this concern (6,7). 
The purpose of the present analysis was to examine survival 
and mode of death over a 7-year period for all patients 
referred to a single center for evaluation of advanced heart 
failure and consideration for heart ransplantation. During this 
time, therapy reflected a systematic approach to hemodynamic 
and arrhythmia management, which evolved by consensus of 
the team to include new trial results. 
Methods 
Patients. From January 1986 to April 1993, 737 consecu- 
tive patients with advanced, ilated heart failure (all with left 
ventricular ejection fraction <0.40) were referred to the 
University of California at Los Angeles cardiomyopathy ser- 
vice, admitted to the hospital for optimization of medical 
therapy in conjunction with evaluation for heart transplanta- 
tion and then discharged from the hospital. Clinical and 
hemodynamic variables were prospectively collected uring 
the hospital period (see later) and entered into a data base. 
Three patient groups were defined by date of initial hospital 
admission: group I from 1986 to 1988; group II in the transition 
period from 1989 to 1990; and group III from January 1991 to 
April 1993. Intervals were selected according to changes in 
therapy described herein. 
Management of heart failure. Medical management was 
under the direction of the same physicians throughout the time 
period studied. After undergoing right heart catheterization 
for assessment of pulmonary pressures, all patients with initial 
pulmonary capillary wedge pressure >20 mm Hg or cardiac 
index <2.2 liters/rain per m 2 received further adjustment of 
therapy under hemodynamic guidance. As previously de- 
scribed (8), the combination of elevated systemic vascular 
resistance and filling pressures was treated with nitroprusside 
and diuretic drugs to approach emodynamic goals of systemic 
vascular resistance <1,200 dynes-s-cm -5, pulmonary capillary 
wedge pressure -<15 mm Hg and right atrial pressure 
-<7 mm Hg while maintaining systolic blood pressure 
->80 mm Hg, which were then matched on combinations of
oral vasodilators (captopril or hydralazine, orboth, with isosor- 
bide dinitrate). 
Before 1988, the choice of oral vasodilator (captopril or 
hydralazine in combination with isosorbide dinitrate) was 
made arbitrarily by the attending cardiomyopathy team mem- 
ber. Unacceptable side effects or failure of the initial vasodi- 
lator to achieve the desired hemodynamic response of filling 
pressure and systemic vascular esistance l d to use of the 
alternative. Between September 1988 and August 1989, the 
initial vasodilator was chosen randomly for 117 patients in the 
Hy-C trial (9) comparing captopril with hydralazine. During 
this time, isosorbide dinitrate was given to all patients with 
coronary artery disease or inadequate hemodynamic response 
to captopril or hydralazine as the primary vasodilator. After 
the V-HeFT and Hy-C trials (3,9) demonstrated greater e- 
duction of mortality with angiotensin-converting e zyme inhi- 
bition, the cardiomyopathy team implemented a change in 
policy in late 1990 specifying that an angiotensin-converting 
enzyme inhibitor (usually captopril) be tried as the initial 
vasodilator. Because the survival benefit seen in the Hy-C trial 
with captopril occurred when 85% of patients were also taking 
isosorbide dinitrate, nitrate therapy was subsequently given to 
all patients if tolerated. Failure to achieve hemodynamic goals 
on this combination led to the addition of hydralazine, with 
continued captopril therapy if tolerated. Therapy with digoxin 
was at the discretion of the specific team physician. Anticoag- 
ulation was prescribed primarily for patients who, in addition 
to marked ventricular dilation, had atrial fibrillation, previous 
embolic events or mobile intracardiac thrombi observed on the 
echocardiogram. No patients underwent trials with investiga- 
tional drugs during this period. 
Arrhythmia management. During the hospital period, all 
patients were evaluated by the arrhythmia consultation service 
and questioned specifically about prior antiarrhythmic drug 
use and arrhythrnia symptoms. Before 1989, patients who had 
premature ventricular contractions or atrial fibrillation con- 
trolled with class I antiarrhythmic drugs at the time of referral 
continued to receive these medications. In late 1989, after 
publication of the CAST results (5) showing increased mortal- 
ity with similar agents, the team revised the approach to 
antiarrhythmic therapy. At the time of hospital admission, class 
I antiarrhythmic drugs were discontinued unless they had been 
administered for prophylaxis of sustained ventricular tachycar- 
dia or ventricular fibrillation, usually with efficacy documented 
by electrophysiologic testing. A 24-h electrocardiogram was 
obtained. Amiodarone was recommended for patients with 
nonischemic cardiomyopathy who had a mean of >40 ventric- 
ular ectopic beats/h or two or more episodes of nonsustained 
ventricular tachycardia (>3 consecutive beats); for patients 
with prior myocardial infarction who had a mean of >6 
ventricular ectopic beats/h or any ventricular tachycardia (>3 
consecutive beats); and for atrial fibrillation or flutter. The 
following were considered contraindications to amiodarone 
therapy: prior amiodarone intolerance, first-degree or higher 
atrioventricular (AV) block, bradycardia <60 beats/min, he- 
patic transaminases levated more than twice normal and a 
pulmonary diffusing capacity or forced vital capacity <60% of 
predicted normal in patients accepted for future heart trans- 
plantation. Amiodarone was administered as600 mg daily for 
2 weeks, then 400 mg daily for 2 weeks, then 200 mg daily. 
There was careful attention to adjusting digoxin and warfarin 
doses as amiodarone therapy was initiated. Cardioversion was 
recommended to patients who remained in atrial fibrillation 
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Table 1. Patient Characteristics 
1986-1988 1989-1990 1991-1993 p 
(n = 243) (n = 228) (n = 266) Value 
Male (%) 78 81 80 0.66 
Age (yr) 49 + 13 52 +_ 12 53 _+ 12 0.0001 
CAD (%) 44 54 48 0.11 
NYHA functional class IV (%) 63 59 54 0.14 
Pacemaker (%) 6 9 10 0.23 
Cardiac arrest (%) 13 11 8 0.2 
Atrial fibrillation (%) 19 24 25 0.24 
Syncope (%) 14 16 19 0.35 
LVEF (%) 0.19 ± 0.06 0.22 _+ 0.07 0.23 +_ 0.07 < 0.0001 
LVDI (mm/m z) 40 ± 6 40 +_ 7 39 _+ 6 0.25 
Hemodynamic variables 
On admission 
SBP (mm Hg) 107 ± 17 110 ± 19 113 ± 17 < 0.0001 
HR (beats/rain) 92 + 18 90 ± 17 90 + 18 0.23 
RA (ram Hg) 12 + 7 11 _+ 7 11 +- 6 0.14 
PAsys (mm Hg) 52 + 18 49 _+ 16 50 _+ 17 0.05 
PCW (ram Hg) 26 _+ 10 24 + 10 23 +_ 10 0.001 
CI (liters/mm 2) 2.1 + 0.7 2.1 + 0.7 2.1 ± 0.7 0.7 
Before discharge 
SBP (ram Hg) 100 + 15 102 ± 16 103 _+ 16 0.08 
HR (beats/min) 92 ± 16 88 ± 16 87 ± 16 0.001 
RA (mm Hg) 7 ± 4 7 ± 4 7 _+ 4 0.38 
PAsys (ram Hg) 4t) +_ 12 40 _+ 13 38 ± 12 0.16 
PCW (mm Hg) 16 ± 6 15 _+ 6 15 _+ 6 0.15 
CI (liters/ram 2) 2.6 ± 0.6 2.6 +_ 0.6 2.5 -- 0.6 0.03 
Serum Na (mEq/liter) 136 + 5 135 ± 5 135 + 4 0.24 
Data presented are mean value ± SD or percent of patients. CAD = coronary artery disease; CI = cardiac index; HR = heart rate; LVEF = left ventricular ejection 
fraction; LVDI = left ventricular diastolic dimension i dex; Na = sodium; NYHA = New York Heart Association; PAsys = systolic pulmonary artery pressure; PCW = 
pulmonary capillary wedge pressure; SBP - systolic arterial pressure. 
after 4 to 6 weeks of amiodarone therapy (10). Patients who 
were receiving therapy to prevent recurrence of sustained 
ventricular tachycardia or ventricular fibrillation were contin- 
ued on that therapy, which had usually been selected by 
electrophysiologic testing before referral. 
Follow-up. Patients were followed up at the Ahmanson- 
UCLA Cardiomyopathy Center in conjunction with their re- 
ferring physician. Patient status was determined by telephone 
interview of patient, family or physician in April 1994 so that 
all surviving patients had a minimum of 1 year of follow-up. 
Only 19 patients (2.5%) were lost to follow-up. Sudden death 
was defined as death occurring instantaneously, within 15 min 
of a change in symptoms or unexpectedly during sleep. 
Statistics. Statistical analysis was performed with BMDP 
programs (11). Continuous variables were compared with 
analysis of variance with the Tukey method applied to assess 
individual differences between groups (BMDP program 7D). 
Chi-square tests were used to evaluate proportions. One-year 
cumulative probabilities of sudden death and total mortality 
were constructed using the Kaplan-Meier method and com- 
pared with the Mantel-Cox test. Patients who underwent heart 
transplantation were removed from survival analysis at the 
date of operation. 
To adjust for baseline differences other than changes in 
therapy, Cox proportional hazards models were constructed 
for total mortality and for sudden death end points. The 
variables assessed were age; left ventricular ejection fraction; 
serum sodium levels; admission and predischarge systolic 
blood, pulmonary capillary wedge and pulmonary artery sys- 
tolic pressures; predischarge cardiac index and heart rate; 
history of syncope, atrial fibrillation or cardiac arrest; coronary 
artery disease; permanent pacemaker; implantable defibrilla- 
tor; and entry after year 1990. Variables were entered into a 
stepwise model if their level of significance was <0.2. Treat- 
ment after 1990 was then entered into the model. A second 
model was then constructed that included amiodarone, class I 
antiarrhythmic drugs and angiotensin-converting enzyme in- 
hibitors to determine whether the improvement in survival 
after 1990 was independent of these changes in therapy. The 
606 patients with complete data for all of the variables were 
included in the multivariate analyses. 
Results 
At the time of hospital admission, all groups defined by 
period of referral had severely depressed left ventricular 
function, poor functional class and a similar incidence of 
syncope, prior cardiac arrest and atrial fibrillation (Table 1). 
Patients referred from 1986 to 1988 were younger, and the 
prevalence of coronary artery disease was slightly, although not 
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Table 2. Therapy at Discharge 
P 
1986-1988 1989-1990 1991-1993 Value 
ACEI 46 57 86 < 0.0001 
Hydralazine 42 38 19 < 0.0001 
Amiodarone 10 49 53 < 0.0001 
Class I AAD 31 16 7 < 0.0001 
Digoxin 39 70 72 < 0.0001 
Warfarin 24 36 42 < 0.0001 
Nitrates 68 64 77 < 0.0001 
ICD 0.8 5 5 0.02 
Data presented are percent of patients. AAD = antiarrhythmic drugs; 
ACEI = angiotensin-converting enzyme inhibitors; ICD = implantable cardio- 
verter-defibrillator. 
statistically, lower. Before 1989, mean left ventricular ejection 
fraction and hemodynamic variables on admission were slightly 
worse than after 1989, but mean serum sodium was 135 
mEq/liter after 1989 compared with 136 mEq/liter before, and 
all three groups achieved similar hemodynamic variables on 
tailored therapy, with a reduction in cardiac filling pressures 
and increase in cardiac index (Table 1). After 1990, final heart 
rate and cardiac index were slightly lower, probably because of 
less frequent use of hydralazine and greater use of amiodarone 
(see later). 
By design, medications at hospital discharge changed mark- 
edly over the study period (Table 2). The administration of 
angiotensin-converting e zyme inhibitors increased from 46% 
to 86% of patients, whereas hydralazine use decreased from 
42% to 19%. Administration of class I antiarrhythmic drugs 
decreased from 31% to 7% of patients, and amiodarone 
administration increased from 10% to 53%. Presence of 
implantable cardioverter-defibrillators increased from 0.8% to 
5% of patients, all of whom had a prior history of sustained 
ventricular tachycardia or ventricular fibrillation. Digoxin ad- 
ministration increased from 39% to 72% of patients. Long- 
term anticoagulation with warfarin was also used more fre- 
quently after 1988. 
Survival and sudden death. Cumulative mortality and sud- 
den death during the year after evaluation decreased uring 
the study period (Fig. 1 and 2). The total mortality rate 
decreased from 33% during 1986 to 1988 to 16% during 1991 
to 1993 (p = 0.0001). Sudden death decreased from 20% to 8% 
(p = 0.0006). The improvement in outcome occurred espite a
similar proportion of patients accepted for transplantation i  
each group, a trend toward fewer patients undergoing trans- 
plantation and a longer median time to transplantation after 
1990 (Table 3). Once accepted, candidates underwent trans- 
plantation solely on the basis of size, blood type and time 
listed, without preference to clinical severity, except for the few 
patients warranting urgent transplantation (7% before 1989, 
8% after 1990). 
To adjust for baseline differences between groups excluding 
therapies, Cox proportional hazards models were constructed. 
The variables that met criteria for inclusion (p < 0.2) in the 
models are shown in Table 4. Treatment after 1990 was 
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Figure 1. Cumulative deaths from all causes for patients evaluated 
during 1986 to 1988, 1989 to 1990 and 1991 to 1993. Total mortality 
was significantly less for patients evaluated after 1990 than during 1986 
to 1988 (p = 0.0001) or 1989 to 1990 (p = 0.001). Numbers below 
graph = number of patients remaining in each time period. 
associated with a lower total mortality rate (risk ratio [RR] 
0.55, 95% confidence interval [CI] 0.37 to 0.84). When therapy 
with angiotensin-converting enzyme inhibitors (p = 0.02), 
amiodarone (p = 0.19) and class I antiarrhythmic drugs (p = 
0.19) was entered into the model, treatment after 1990 was no 
longer independently associated with better survival (RR 0.68, 
95% CI 0.43 to 1.1). Thus, in this model the improvement in
survival over time could largely be explained by these changes 
in therapy. 
In the multivariate model for sudden death, patients treated 
after 1990 had a lower risk (RR 0.56, 95% CI 0.32 to 0.99). 
When therapy with angiotensin-converting e zyme inhibitors 
(p = 0.002) was entered into the model, treatment after 1990 
was not independently associated with a greater sudden death 
Figure 2. Cumulative sudden deaths for patients evaluated uring 
1986 to 1988, 1989 to 1990 and 1991 to 1993. Sudden death was 
significantly less for patients evaluated during 1991 to 1993 than during 
1986 to 1988 (p = 0.0006), but the difference did not reach statistical 
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Table 3. Heart Transplantation 
P 
1986-1988 1989-1990 1991-1993 Value 
Accepted for waiting list (%) 52 52 56 0.52 
Transplantation (%) 33 35 29 0.27 
Urgent ransplantation (%) 7 11 8 0.29 
Median time to 195 178 216 
transplantation (days) 
Unless otherwise indicated, data presented are percent of patients. 
risk (RR 0.76, 95% CI 0.41 to 1.4). Therapy with amiodarone 
(p = 0.68) and class I drugs (p = 0.21) did not meet criteria for 
entry into the multivariate model for sudden death. 
Discuss ion  
Heart transplantation has improved survival and quality of 
life but can be provided to <2,500 patients with heart failure/ 
year (7). Its promise attracts patients with heart failure to 250 
centers in the world, where attempts are also made to optimize 
medical therapy for candidates on the outpatient waiting list 
for transplantation a d for ineligible patients. The severity of 
illness and need for individualization of therapy in such 
patients limit their inclusion in multicenter t ials, such as the 
V-HeFT (3) and SOLVD (2) trials, in which class IV heart 
failure was present in 0.35% and 1.7% of patients, respectively 
(2,3). The present study of patients with severe heart failure 
demonstrates relative decreases in the total mortality and 
sudden death rates of 51% and 70% in temporal relation to 
changes in medical therapy for heart failure and arrhythmias, 
which were instituted on the basis of published trial results. 
Patients were managed according to uniform guidelines at a 
single center. All patients discharged after hospital admission 
for heart failure and transplant evaluation were included. No 
patients were treated with investigational inotropic medica- 
Table 4. Multivariate Analysis for Total Mortality and Sudden Death 
Total Mortality Sudden Death 
Risk Ratio 95% CI Risk Ratio 95% CI 
After 1990 0.55 0.37-0.84 0.56 0.32-0.99 
Serum Na (mEqjliter) 0.93 0.89-0.96 0.97 0.92-1.03 
SBP adm (nun Hg) 0.99 0.98-1.0 
PCW adm (mm Hg) 1.01 0.99-1.03 
PCW final (mm Hg) 1.05 1.02-1.09 1.05 0.99-1.1 
Atrial fib 1.3 0.9-2.0 
Cardiac arrest 2,1 1.3-3.3 2.1 1.1-3.9 
Syncope 1.8 1.2-2.7 2.4 1.4-4.3 
LVEF 0.98 0.95-1.2 
PAsys final (mm Hg) 1.02 0.99-1.04 
Age (yr) 0 .97 0.95-0.99 
Variables with p -< 0.2 were included in the models. For continuous 
variables, the risk ratio reflects the change in risk for a 1-unit change in the 
variable, adm = on admission; CI = confidence interval; fib = fibrillation; other 
abbreviations a  in Table 1. 
tions, some of which have subsequently been associated with 
increased mortality (12,13). 
Vasodilator therapy. Before 1989, it was known that mor- 
tality in heart failure was reduced by either hydralazine 
combined with isosorbide dinitrate or angiotensin-converting 
enzyme inhibitors (4,14). From 1983 to 1988, the initial oral 
vasodilator administered was chosen by the attending cardio- 
myopathy team physician based on clinical judgment or, in 104 
patients, according to a randomization scheme (9). Subse- 
quently, captopril and enalapril were shown to improve sur- 
vival more than the hydralazine and isosorbide dinitrate com- 
bination (3,9). The treatment protocol was then altered to 
include angiotensin-converting e zyme inhibitors as the pre- 
ferred vasodilator, adding or changing to hydralazine only in 
the event of a poor hemodynamic response or intolerance. 
These results continue to support the use of angiotensin- 
converting enzyme inhibitors as first-line therapy in patients 
with advanced heart failure (2,15). Although the separate 
effects of oral nitrates have not been assessed by a randomized 
trial, isosorbide dinitrate was routinely prescribed at this center 
after 1990, because the captopril/nitrate combination was 
associated with a relatively low mortality in the Hy-C trial (9). 
Arrhythmia management. Angiotensin-converting enzyme 
inhibitors decrease sudden death compared with the 
hydralazine-isosorbide initrate combination, but sudden 
death still accounts for 28% to 68% of deaths in recent rials 
(3,4,9,15-18). There are several possible causes of sudden 
death and even a variety of definitions among investigators, 
making this end point less reliable. However, ventricular 
arrhythmias are likely to be important (18). Nonsustained 
ventricular tachycardia and complex ventricular ectopic activity 
are observed in 20% to 80% of patients with heart failure, and 
the optimal approach to management is unclear. Early in the 
present study, class I antiarrhythmic drugs were continued in 
patients receiving these medications before referral. In 1989 it 
became clear that treatment with encainide or flecainide 
increased mortality after myocardial infarction (5). In an 
analysis of the nonrandomized patients in our center up to that 
time, patients treated with class I drugs had a higher risk of 
sudden death than those treated with amiodarone or receiving 
no antiarrhythmic drugs. A policy was then instituted to 
discontinue class I antiarrhythmic drugs unless they had been 
effective in controlling sustained ventricular arrhythmias. This 
approach as been further supported by the recent report of 
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Flaker et al. (19) that antiarrhythmic drug therapy was associ- 
ated with increased mortality in patients with atrial fibrillation 
and heart failure. In the current study, amiodarone was 
recommended for patients with frequent ventricular ectopic 
activity or if an antiarrhythmic agent was required for preven- 
tion of atrial fibrillation. Amiodarone was selected because it is 
well tolerated uring long-term therapy in patients with heart 
failure, and initial studies (20-23) suggested that it was 
unlikely to increase mortality, at least in postinfarction pa- 
tients. This approach to arrhythmia management appears to be 
reasonably safe because it was followed by a dramatic reduc- 
tion in sudden death. A recent randomized trial (24) found 
that amiodarone improved survival in severe heart failure. 
Amiodarone did not affect survival in another trial (25) in 
patients with less severe heart failure. Our data cannot ascer- 
tain the relative importance of amiodarone, withdrawal of class 
I drugs and increased use of angiotensin-converting e zyme 
inhibitors. Precautions that were taken with regard to antiar- 
rhythmic therapy deserve emphasis. In patients with heart 
failure, bradyarrhythmias are a cause of sudden death that can 
be provoked by amiodarone (6,22). Amiodarone was not 
administered to patients with evidence of sinus or AV node 
dysfunction, even if these were asymptomatic. Antiarrhythmic 
drugs were withdrawn only in patients without a history of 
sustained ventricular tachycardia or cardiac arrest and were 
withdrawn during ECG monitoring in hospital. 
Digoxin and anticoagulation. The use of digoxin also in- 
creased over the study period, during which several trials 
(26-28) demonstrated benefit of digoxin on ventricular func- 
tion, exercise capacity, clinical stability and autonomic balance. 
The effect of digoxin on mortality is not yet known. The use of 
anticoagulation also increased, but the expected impact of this 
change on mortality is slight because of the low incidence of 
embolic events in this population (29). 
Transplantation. Although -50% of our patients were 
candidates for transplantation, only 33% of those seen before 
1989 and 29% after 1990 underwent transplantation (Table 3). 
Once a patient is accepted for addition to the outpatient 
waiting list, selection for transplantation depends on matching 
with an available donor for body size and blood type, with 
further priority based on the duration of time the patient has 
been on the waiting list. Time of transplantation is a relatively 
unbiased censored event in the survival analysis except when 
deterioration requires urgent ransplantation, which occurred 
in only 7% of patients before 1989 and 8% after 1990. 
Study limitations. The present study was not a randomized 
trial of therapy. We cannot exclude the possibility that subtle 
changes in factors that were not assessed, such as better patient 
compliance with risk factor modifications, moking cessation 
and diet, may have contributed to better outcomes. Commu- 
nity awareness of therapy for heart failure may have improved. 
These factors may explain the referral of patients with slightly 
less baseline hemodynamic compromise during the later years. 
However, differences were relatively small, and the hemody- 
namic profiles before hospital discharge were similar. The 
average serum sodium levels also suggest comparable severity 
of heart failure in the later group. In the proportional hazards 
model, those patients treated after 1990 had lower mortality 
and sudden death after adjustment for baseline differences. 
Furthermore, angiotensin-converting enzyme inhibitors or 
change in antiarrhythmic therapies, or both, appeared largely 
to account for the reduction in mortality. The follow-up 
periods were restricted to 1 year to allow comparison of the 
treatment groups. 
Clinical implications. The present study demonstrates 
over an 8-year period in a single center a marked improvement 
in 1-year survival and reduction in sudden death in of patients 
with advanced heart failure. This result is most likely related to 
improvements in medical management of heart failure and 
arrhythmias. The reduction in sudden death risk to 8% at 1 
year for patients discharged after eferral to a transplant center 
indicates that most ambulatory patients may safely be main- 
tained on optimal medical therapy until clinical deterioration 
mandates transplantation. 
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